Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency\, the Primary Cause of the Most Common Inherited Optic Nerve Disorder